News

Video

Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA Study

Author(s):

Alexander Spira, MD, PhD, FACP

A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.

Related Videos
Sandip P. Patel, MD
Alissa J. Cooper, MD
Joshua K. Sabari, MD
Eric Kumar Singhi, MD
Eric Kumar Singhi, MD
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Karen L. Reckamp, MD, MS
5 KOLs featured in this series
Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.
Cameron James Oswalt MD, fellow, Hematology-Oncology, assistant professor, medicine, Department of Medicine, Duke University School of Medicine
Related Content
Solange Peters, MD, PhD
September 4th 2024

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

The OncFive: Top Oncology Articles for the Week of 8/25
August 31st 2024

The OncFive: Top Oncology Articles for the Week of 8/25

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Revisit Every OncLive On Air Episode From August 2024
August 30th 2024

Revisit Every OncLive On Air Episode From August 2024

Marjorie Green, MD
August 29th 2024

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC